Kytril (Granisetron)

Granisetron works by selectively blocking peripheral and central 5‑HT3 receptors. By preventing serotonin from binding to these receptors, it interrupts the neural pathways that initiate the vomiting reflex, thereby reducing nausea and vomiting.

The exact dose of Kytril is determined by the prescribing clinician based on the patient’s condition, treatment protocol, and other individual factors. Healthcare professionals set the appropriate dosage and schedule.

Safety data for Kytril in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To order Kytril, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both Kytril (granisetron) and ondansetron are 5‑HT3 receptor antagonists used for similar indications. Granisetron has a longer half‑life, which may allow less frequent dosing, while ondansetron is available in both oral and injectable forms. Choice depends on clinical judgment, patient preference and specific treatment protocols.

Kytril should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in humid or excessively hot environments.

Kytril is administered orally, typically as a tablet or oral solution, according to the prescriber’s instructions. It is taken with or without food, and the exact timing relative to chemotherapy or surgery is determined by the treating physician.

The most serious risks include QT interval prolongation, which can lead to cardiac arrhythmias, severe allergic reactions such as anaphylaxis, and, rarely, serotonin syndrome when combined with other serotonergic drugs. Patients should be monitored for these events.

Kytril should be avoided in patients with known hypersensitivity to granisetron or any component of the formulation, and in individuals with a history of significant QT prolongation or uncontrolled cardiac arrhythmias. Caution is also advised for patients taking other QT‑prolonging agents.